小细胞肺癌患者的 PCI 治疗：免疫疗法时代的新视角。

IF 21 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology Pub Date : 2024-11-15 DOI:10.1016/j.jtho.2024.11.011

Antonin Levy, Chad G Rusthoven, Paul D Brown, Cécile Le Péchoux, Corinne Faivre-Finn

{"title":"小细胞肺癌患者的 PCI 治疗：免疫疗法时代的新视角。","authors":"Antonin Levy, Chad G Rusthoven, Paul D Brown, Cécile Le Péchoux, Corinne Faivre-Finn","doi":"10.1016/j.jtho.2024.11.011","DOIUrl":null,"url":null,"abstract":"Prophylactic cranial irradiation (PCI) has long been used for small-cell lung cancer (SCLC) to reduce the risk of brain metastases and potentially improve overall survival. However, recent immunotherapy trials have provided limited data on its impact, as few patients were treated with PCI. The ADRIATIC trial demonstrated improved outcomes with consolidation immunotherapy in limited-stage SCLC, and PCI was a stratification factor. Notably, patients receiving PCI in both arms had better outcomes compared to those who did not. Ongoing studies, such as EORTC-1901 PRIMALung (NCT04790253) and SWOG 1827-MAVERICK (NCT04155034), are further investigating PCI's role in the era of immunotherapy, highlighting its potential importance in evolving treatment strategies.","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PCI for Patients with Small Cell Lung Cancer: A New Perspective in the Immunotherapy Era.\",\"authors\":\"Antonin Levy, Chad G Rusthoven, Paul D Brown, Cécile Le Péchoux, Corinne Faivre-Finn\",\"doi\":\"10.1016/j.jtho.2024.11.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Prophylactic cranial irradiation (PCI) has long been used for small-cell lung cancer (SCLC) to reduce the risk of brain metastases and potentially improve overall survival. However, recent immunotherapy trials have provided limited data on its impact, as few patients were treated with PCI. The ADRIATIC trial demonstrated improved outcomes with consolidation immunotherapy in limited-stage SCLC, and PCI was a stratification factor. Notably, patients receiving PCI in both arms had better outcomes compared to those who did not. Ongoing studies, such as EORTC-1901 PRIMALung (NCT04790253) and SWOG 1827-MAVERICK (NCT04155034), are further investigating PCI's role in the era of immunotherapy, highlighting its potential importance in evolving treatment strategies.\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2024-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jtho.2024.11.011\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtho.2024.11.011","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

长期以来，预防性颅脑照射（PCI）一直被用于小细胞肺癌（SCLC）的治疗，以降低脑转移的风险，并有可能提高总生存率。然而，最近的免疫疗法试验对其影响提供的数据有限，因为只有少数患者接受了PCI治疗。ADRIATIC 试验表明，在有限分期的 SCLC 中，巩固免疫疗法可改善疗效，而 PCI 是一个分层因素。值得注意的是，两组接受 PCI 治疗的患者与未接受 PCI 治疗的患者相比，疗效更好。EORTC-1901 PRIMALung（NCT04790253）和SWOG 1827-MAVERICK（NCT04155034）等正在进行的研究正在进一步研究PCI在免疫疗法时代的作用，突出了PCI在不断发展的治疗策略中的潜在重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

PCI for Patients with Small Cell Lung Cancer: A New Perspective in the Immunotherapy Era.

Prophylactic cranial irradiation (PCI) has long been used for small-cell lung cancer (SCLC) to reduce the risk of brain metastases and potentially improve overall survival. However, recent immunotherapy trials have provided limited data on its impact, as few patients were treated with PCI. The ADRIATIC trial demonstrated improved outcomes with consolidation immunotherapy in limited-stage SCLC, and PCI was a stratification factor. Notably, patients receiving PCI in both arms had better outcomes compared to those who did not. Ongoing studies, such as EORTC-1901 PRIMALung (NCT04790253) and SWOG 1827-MAVERICK (NCT04155034), are further investigating PCI's role in the era of immunotherapy, highlighting its potential importance in evolving treatment strategies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Thoracic Oncology 医学-呼吸系统

CiteScore

36.00

自引率

3.90%

发文量

1406

审稿时长

13 days

期刊介绍： Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.